Heinz-Peter Schultheiss1,2, Cornelia Piper3, Olaf Sowade4, Finn Waagstein5, Joachim-Friedrich Kapp4, Karl Wegscheider6, Georg Groetzbach4, Matthias Pauschinger7,8, Felicitas Escher7,9, Eloisa Arbustini10, Harald Siedentop4, Uwe Kuehl7,9. 1. Department of Cardiology, Campus Benjamin Franklin, Charite-Universitätsmedizin Berlin, Berlin, Germany. heinz-peter.schultheiss@charite.de. 2. Institute for Cardiac Diagnostics and Therapy (IKDT), Moltkestr. 31, 12203, Berlin, Germany. heinz-peter.schultheiss@charite.de. 3. Kardiologische Klinik, Herz- und Diabetes Zentrum NRW, Bad Oeynhausen, Germany. 4. Bayer Health Care AG, Berlin, Germany. 5. Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. 6. Institut für Biometrie und Epidemiologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany. 7. Department of Cardiology, Campus Benjamin Franklin, Charite-Universitätsmedizin Berlin, Berlin, Germany. 8. Department of Cardiology, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nuremberg, Germany. 9. Institute for Cardiac Diagnostics and Therapy (IKDT), Moltkestr. 31, 12203, Berlin, Germany. 10. Centre for Inherited Cardiovascular Diseases and Transplant Research Area, IRCCS Foundation Policlinico San Matteo, Univ di Pavia, Pavia, Italy.
Abstract
BACKGROUND: Chronic viral infections of the heart are considered one antecedent event leading to progressive dysfunction of the myocardium, often with an impaired prognosis due to a virus- or immune-mediated myocardial injury. Symptomatic treatment does not influence the viral cause of heart failure, and the effect of antiviral treatment has not been determined, yet. METHODS AND RESULTS: In this phase II study 143 patients with symptoms of heart failure and biopsy-based confirmation of the enterovirus (EV), adenovirus, and/or parvovirus B19 genomes in their myocardial tissue were randomly assigned to double-blind treatment, and received either placebo (n = 48) or 4 × 10(6) (n = 49) and 8 × 10(6) IU (n = 46) interferon beta-1b (IFN-β-1b) for 24 weeks, in addition to standard heart failure treatment. Patients with active myocarditis or other specific causes of heart failure were excluded. Compared to placebo, virus elimination and/or virus load reduction was higher in the IFN-β-1b groups (odds ratio 2.33, p = 0.048), similarly in both interferon groups and both strata. IFN-β-1b treatment was associated with favourable effects on NYHA functional class (p = 0.013 at follow-up week 12), improvement in quality of life (Minnesota Heart Failure score; p = 0.032 at follow-up week 24) and patient global assessment (follow-up week 12 to follow-up week 24; p = 0.039). The frequency of adverse cardiac events was not higher in the IFN-β-1b groups compared to the placebo group. CONCLUSIONS:Immunomodulatory IFN-β-1b treatment is a well-tolerated and safe treatment option, leading to effective virus clearance or reduction of the virus load in patients with chronic viral cardiomyopathy. Favourable clinical effects assess quality of life, NYHA functional class, and patient global assessment. ClinicalTrials.gov identifier: NCT001185250.
RCT Entities:
BACKGROUND:Chronic viral infections of the heart are considered one antecedent event leading to progressive dysfunction of the myocardium, often with an impaired prognosis due to a virus- or immune-mediated myocardial injury. Symptomatic treatment does not influence the viral cause of heart failure, and the effect of antiviral treatment has not been determined, yet. METHODS AND RESULTS: In this phase II study 143 patients with symptoms of heart failure and biopsy-based confirmation of the enterovirus (EV), adenovirus, and/or parvovirus B19 genomes in their myocardial tissue were randomly assigned to double-blind treatment, and received either placebo (n = 48) or 4 × 10(6) (n = 49) and 8 × 10(6) IU (n = 46) interferon beta-1b (IFN-β-1b) for 24 weeks, in addition to standard heart failure treatment. Patients with active myocarditis or other specific causes of heart failure were excluded. Compared to placebo, virus elimination and/or virus load reduction was higher in the IFN-β-1b groups (odds ratio 2.33, p = 0.048), similarly in both interferon groups and both strata. IFN-β-1b treatment was associated with favourable effects on NYHA functional class (p = 0.013 at follow-up week 12), improvement in quality of life (Minnesota Heart Failure score; p = 0.032 at follow-up week 24) and patient global assessment (follow-up week 12 to follow-up week 24; p = 0.039). The frequency of adverse cardiac events was not higher in the IFN-β-1b groups compared to the placebo group. CONCLUSIONS: Immunomodulatory IFN-β-1b treatment is a well-tolerated and safe treatment option, leading to effective virus clearance or reduction of the virus load in patients with chronic viral cardiomyopathy. Favourable clinical effects assess quality of life, NYHA functional class, and patient global assessment. ClinicalTrials.gov identifier: NCT001185250.
Authors: Q T Nguyen; C Sifer; V Schneider; X Allaume; A Servant; F Bernaudin; V Auguste; A Garbarg-Chenon Journal: J Clin Microbiol Date: 1999-08 Impact factor: 5.948
Authors: H J Why; B T Meany; P J Richardson; E G Olsen; N E Bowles; L Cunningham; C A Freeke; L C Archard Journal: Circulation Date: 1994-06 Impact factor: 29.690
Authors: Kati Hokynar; Maria Söderlund-Venermo; Maria Pesonen; Annamari Ranki; Olli Kiviluoto; Esa K Partio; Klaus Hedman Journal: Virology Date: 2002-10-25 Impact factor: 3.616
Authors: Neil E Bowles; Jiyuan Ni; Debra L Kearney; Matthias Pauschinger; Heinz-Peter Schultheiss; Robert McCarthy; Joshua Hare; J Timothy Bricker; Karla R Bowles; Jeffrey A Towbin Journal: J Am Coll Cardiol Date: 2003-08-06 Impact factor: 24.094
Authors: Ulf K Radunski; Gunnar K Lund; Dennis Säring; Sebastian Bohnen; Christian Stehning; Bernhard Schnackenburg; Maxim Avanesov; Enver Tahir; Gerhard Adam; Stefan Blankenberg; Kai Muellerleile Journal: Clin Res Cardiol Date: 2016-07-07 Impact factor: 5.460